In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae | Zendy

Susanne Jacobsson | Zendy; Daniel Golparian | Zendy; Nicole E. Scangarella-Oman | Zendy; Magnus Unemo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae

Author(s) -

Susanne Jacobsson,

Daniel Golparian,

Nicole E. Scangarella-Oman,

Magnus Unemo

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky162

Subject(s) - neisseria gonorrhoeae , microbiology and biotechnology , etest , antimicrobial , ciprofloxacin , agar dilution , efflux , antibiotic resistance , biology , antibiotics , drug resistance , cephalosporin , minimum inhibitory concentration , genetics

Increased antimicrobial resistance surveillance and new effective antimicrobials are crucial to maintain treatable gonorrhoea. We examined the in vitro activity of gepotidacin, a novel triazaacenaphthylene, and the effect of efflux pump inactivation on clinical Neisseria gonorrhoeae isolates and international reference strains (n = 252) and compared gepotidacin with antimicrobials currently or previously recommended for gonorrhoea treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research